Chemours’ (CC) Neutral Rating Reiterated at Mizuho

Mizuho reaffirmed their neutral rating on shares of Chemours (NYSE:CC) in a research report sent to investors on Wednesday, Marketbeat.com reports. They currently have a $15.00 price target on the specialty chemicals company’s stock, down from their prior price target of $18.00.

A number of other research analysts also recently weighed in on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $16.00 price target on shares of Chemours in a report on Friday, October 9th. Truist Financial reduced their price objective on Chemours from $30.00 to $24.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Barclays started coverage on Chemours in a research note on Monday. They issued an “equal weight” rating and a $16.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 13th. Finally, UBS Group lowered their target price on Chemours from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Monday, October 5th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $18.09.

Chemours Trading Down 1.5%

Shares of CC opened at $12.71 on Wednesday. The business’s 50-day moving average price is $14.69 and its 200 day moving average price is $18.87. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. The stock has a market capitalization of $1.91 billion, a P/E ratio of -6.66 and a beta of 1.41. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the previous year, the business earned ($2.54) earnings per share. The business’s quarterly revenue was down 1.5% compared to the same quarter last year. Analysts expect that Chemours will post 0.84 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 15th. Shareholders of record on Friday, August 14th were paid a $0.0875 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.35 dividend on an annualized basis and a yield of 2.8%. Chemours’s payout ratio is -18.32%.

Insiders Place Their Bets

In other Chemours news, CEO Denise Dignam bought 3,378 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was bought at an average cost of $14.95 per share, with a total value of $50,501.10. Following the completion of the transaction, the chief executive officer directly owned 339,916 shares of the company’s stock, valued at approximately $5,081,744.20. The trade was a 1.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the purchase, the insider owned 58,547 shares in the company, valued at $909,234.91. The trade was a 3.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 8,663 shares of company stock valued at $130,601 over the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Chemours

Several hedge funds have recently bought and sold shares of CC. The Manufacturers Life Insurance Company acquired a new position in Chemours during the second quarter valued at approximately $1,522,000. Deutsche Bank AG acquired a new stake in shares of Chemours in the second quarter worth $3,291,000. BlackRock Inc. acquired a new stake in shares of Chemours in the second quarter worth $477,769,000. Old West Investment Management LLC acquired a new stake in shares of Chemours in the second quarter worth $7,152,000. Finally, Jefferies Financial Group Inc. bought a new stake in shares of Chemours during the 2nd quarter worth $15,996,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Negative Sentiment: Multiple law firms announced or promoted a securities-fraud class action against Chemours and certain executives. The lawsuit covers investors who purchased CC securities from February 20 through August 4, 2026, with a December 7, 2026 deadline to seek lead-plaintiff status. The allegations include misleading statements or omissions about the reliability of the company’s financial guidance, including claims that management overstated aftermarket demand for Opteon refrigerants and failed to account for sales pulled forward by distributor inventory stocking. The allegations have not been proven in court. Chemours investor alert and class-action lawsuit
• Negative Sentiment: The litigation adds potential legal costs, reputational risk and uncertainty around Chemours’ prior guidance and operating disclosures. One notice said CC shares fell 18.63% in a single session, the event underlying the shareholder claims. Chemours shareholder alert
• Negative Sentiment: Mizuho cut its view on Chemours from “strong buy” or “outperform” to “neutral” and lowered its price target to $15. Barclays also rated the shares “hold.” The moves reinforce a more cautious sell-side outlook and may limit near-term buying interest. Mizuho cuts Chemours price target

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.